Viela Bio Presents Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder in a Plenary Session at the American Academy of Neurology Annual Meeting
Company to hold investor event on May 9th GAITHERSBURG, Md.–(BUSINESS WIRE)–Viela Bio today announced results from a pivotal study of its…